Sonlicromanol - Khondrion
Alternative Names: KH 176Latest Information Update: 27 Jan 2025
At a glance
- Originator Khondrion
- Class Antiparkinsonians; Benzopyrans; Piperidines; Small molecules
- Mechanism of Action Prostaglandin-E synthase inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mitochondrial disorders
- No development reported Parkinson's disease
Most Recent Events
- 10 Jan 2025 Khondrion BV suspends a phase II trial in Mitochondrial disorders (In neonates, In infants, In children, In adolescents) in Netherlands (PO) due to strategic company decision, not related to safety concerns (EudraCT2020-003124-16)
- 14 Nov 2024 US FDA approves IND application for sonlicromanol in Mitochondrial disorders
- 14 Nov 2024 Khondrion plans a pivotal phase III trial in Mitochondrial disorders (PO) in 2025